€7.4bn ‘Just The Start’ For Global COVID-19 Drug & Vaccine Funding Project
Challenges Huge, Calls For IP On Coronavirus Tools To Be Pooled
It’s not enough just to develop new drugs and vaccines for COVID-19. These tools must be made available to all those who need them wherever they are; for this to happen, health systems will need to be strengthened, say the backers of an EU-led funding initiative. Industry says it has already brought considerable resources to the table and stresses that close international cooperation will be vital if the pandemic is to be tackled effectively.
You may also be interested in...
A global collaboration initiative launched by the World Health Organization is intended to foster the development of COVID-19 vaccines, medicines and diagnostics and to make sure they reach all those who need them.
As the European Commission prepares to publish its proposals for overhauling the EU pharmaceutical legislation at the end of the year, member states have been discussing a range of technical and legal issues such as the scope of the centralized approval procedure, the use of electronic product information and the shortage of inspection capacities.
EU member state authorities have been told they can use Jynneos, the US version of Bavarian Nordic’s smallpox vaccine, for the prevention of monkeypox. The bloc is also buying some 110,000 doses of the vaccine, with deliveries expected to begin shortly.